Galapagos NV (NASDAQ:GLPG) Stake Reduced by Monaco Asset Management SAM

Monaco Asset Management SAM cut its holdings in Galapagos NV (NASDAQ:GLPG) by 28.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 15,000 shares of the biotechnology company’s stock after selling 5,999 shares during the quarter. Monaco Asset Management SAM’s holdings in Galapagos were worth $412,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of GLPG. R Squared Ltd purchased a new position in Galapagos in the 4th quarter worth about $26,000. GAMMA Investing LLC increased its stake in Galapagos by 77.4% in the 4th quarter. GAMMA Investing LLC now owns 2,233 shares of the biotechnology company’s stock worth $61,000 after purchasing an additional 974 shares in the last quarter. QRG Capital Management Inc. increased its stake in Galapagos by 21.7% in the 4th quarter. QRG Capital Management Inc. now owns 10,455 shares of the biotechnology company’s stock worth $288,000 after purchasing an additional 1,866 shares in the last quarter. Crossmark Global Holdings Inc. increased its stake in Galapagos by 31.5% in the 4th quarter. Crossmark Global Holdings Inc. now owns 49,163 shares of the biotechnology company’s stock worth $1,352,000 after purchasing an additional 11,777 shares in the last quarter. Finally, Erste Asset Management GmbH purchased a new position in Galapagos in the 3rd quarter worth about $410,000. 32.46% of the stock is currently owned by institutional investors.

Galapagos Trading Down 2.1 %

Shares of NASDAQ:GLPG opened at $25.99 on Friday. The business’s fifty day moving average price is $25.19 and its two-hundred day moving average price is $27.18. Galapagos NV has a fifty-two week low of $22.36 and a fifty-two week high of $34.65.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the company. Barclays reissued an “underweight” rating on shares of Galapagos in a research note on Thursday, January 23rd. Morgan Stanley cut Galapagos from an “equal weight” rating to an “underweight” rating and lowered their target price for the company from $31.00 to $22.00 in a research note on Friday, February 14th. Kepler Capital Markets cut Galapagos from a “hold” rating to a “reduce” rating in a research note on Wednesday, November 20th. Finally, TD Cowen cut Galapagos from a “strong-buy” rating to a “strong sell” rating in a research note on Thursday, January 9th. Five analysts have rated the stock with a sell rating and five have given a hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $26.75.

Galapagos Company Profile

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.